K. Gupta, J. Miller, J. Li, M. Russell, and C. Charbonneau, Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review, Cancer Treatment Reviews, vol.34, issue.3, pp.193-205, 2008.
DOI : 10.1016/j.ctrv.2007.12.001

J. Patard, H. Baumert, J. Corréas, B. Escudier, H. Lang et al., Recommandations en Onco-Urologie 2010 : Cancer du rein, Progr??s en Urologie, vol.20, issue.4, pp.319-339, 2010.
DOI : 10.1016/S1166-7087(10)70048-8

B. Escudier, S. Osanto, B. Ljungberg, C. Porta, J. Wagstaff et al., Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies, Cancer Treatment Reviews, vol.38, issue.2, pp.127-159
DOI : 10.1016/j.ctrv.2011.05.006

B. Escudier, L. Albiges, A. Blesius, Y. Loriot, C. Massard et al., How to select targeted therapy in renal cell cancer, Annals of Oncology, vol.21, issue.Supplement 7, pp.59-62, 2010.
DOI : 10.1093/annonc/mdq371

R. Motzer, J. Bacik, B. Murphy, P. Russo, and M. Mazumdar, Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.20, issue.1, pp.289-96, 2002.
DOI : 10.1200/JCO.2002.20.1.289

M. Sun, S. Shariat, C. Cheng, V. Ficarra, M. Murai et al., Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review, European Urology, vol.60, issue.4, 2011.
DOI : 10.1016/j.eururo.2011.06.041

G. Sonpavde and T. Choueiri, Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma, British Journal of Cancer, vol.26, issue.7, pp.1009-1025, 2012.
DOI : 10.1093/annonc/mdr047

D. Fiore, F. Rigal, O. Ménager, C. Michel, P. Pfister et al., Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib, British Journal of Cancer, vol.17, issue.12, pp.1811-1814, 2011.
DOI : 10.1038/sj.bjc.6604456

P. Bono, J. Rautiola, T. Utriainen, and H. Joensuu, Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma, Acta Oncologica, vol.370, issue.18, 2011.
DOI : 10.1093/jnci/dji174

A. Poprach, T. Pavlik, B. Melichar, I. Puzanov, L. Dusek et al., Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study, Annals of Oncology, vol.23, issue.12, pp.569-73, 2012.
DOI : 10.1093/annonc/mds145

B. Rini, D. Cohen, D. Lu, I. Chen, S. Hariharan et al., Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib, JNCI Journal of the National Cancer Institute, vol.103, issue.9, pp.763-73, 2011.
DOI : 10.1093/jnci/djr128

G. Khan, A. Golshayan, P. Elson, L. Wood, J. Garcia et al., Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol Off J Eur Soc Med Oncol Esmo Safety and activity of sunitinib in elderly patients (? 70 years) with metastatic renal cell carcinoma: a multicenter study, Ann Oncol Off J Eur Soc Med Oncol Esmo Feb, vol.2124, issue.82, pp.1618-1640, 2010.

Y. Sato, T. Yoshizato, Y. Shiraishi, S. Maekawa, Y. Okuno et al., Integrated molecular analysis of clear-cell renal cell carcinoma, Nature Genetics, vol.27, issue.8, pp.860-867, 2013.
DOI : 10.1073/pnas.92.16.7172

B. Ljungberg, S. Campbell, H. Choi, H. Cho, D. Jacqmin et al., The Epidemiology of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.615-636, 2011.
DOI : 10.1016/j.eururo.2011.06.049

R. Mclaughlin and J. , Available from: http://lesdonnees.e-cancer.fr/les-fiches-de-synthese/29-incidence- mortalite/38-ensemble-des-cancers/22-epidemiologie-des-cancers-en-france-metropolitaine- incidence-et-mortalite.html 21. Méjean A, Lebret T. [Prise en charge of metastatic renal carcinoma] The Epidemiology of Renal Cell Carcinoma, Incidence et mortalité [Internet]. Institut National du Cancer, 2008.

A. Lopez-beltran, M. Scarpelli, R. Montironi, Z. Kirkali, A. Mejean et al., 2004 WHO Classification of the Renal Tumors of the Adults, European Urology, vol.49, issue.5, pp.798-805, 2006.
DOI : 10.1016/j.eururo.2005.11.035

S. Fuhrman, L. Lasky, and C. Limas, Prognostic significance of morphologic parameters in renal cell carcinoma, The American Journal of Surgical Pathology, vol.6, issue.7, pp.655-63, 1982.
DOI : 10.1097/00000478-198210000-00007

F. Boulière, M. Crepel, P. Bigot, G. Pignot, T. Bessede et al., Nephronsparing surgery is superior to radical nephrectomy in preserving renal function outcome in tumors larger than 4 cm]. Progrès En Urol J Assoc Française Urol Société Française Urol Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses, J Urol, vol.21183, issue.124, pp.842-501317, 2010.

D. Kunkle, P. Crispen, D. Chen, R. Greenberg, and R. Uzzo, Enhancing Renal Masses With Zero Net Growth During Active Surveillance, The Journal of Urology, vol.177, issue.3, pp.849-853, 2007.
DOI : 10.1016/j.juro.2006.10.073

S. Chawla, P. Crispen, A. Hanlon, R. Greenberg, D. Chen et al., The Natural History of Observed Enhancing Renal Masses: Meta-Analysis and Review of the World Literature, The Journal of Urology, vol.175, issue.2, pp.425-456, 2006.
DOI : 10.1016/S0022-5347(05)00148-5

J. Patard, O. Shvarts, J. Lam, A. Pantuck, H. Kim et al., SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE, The Journal of Urology, vol.171, issue.6, pp.2181-2185, 2004.
DOI : 10.1097/01.ju.0000124846.37299.5e

T. Choueiri, W. Xie, C. Kollmannsberger, S. North, J. Knox et al., The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy, The Journal of Urology, vol.185, issue.1, 2011.
DOI : 10.1016/j.juro.2010.09.012

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, E. Lee et al., Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010.
DOI : 10.1200/JCO.2009.23.9764

B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

I. Temsirolimus, A. Alfa-zisman, A. Pantuck, F. Dorey, J. Said et al., Improved prognostication of renal cell carcinoma using an integrated staging system, N Engl J Med J Clin Oncol Off J Am Soc Clin Oncol, vol.35619, issue.226, pp.2271-81, 2001.

J. Patard, H. Kim, J. Lam, F. Dorey, A. Pantuck et al., Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study, Journal of Clinical Oncology, vol.22, issue.16, pp.3316-3338, 2002.
DOI : 10.1200/JCO.2004.09.104

R. Zigeuner, G. Hutterer, T. Chromecki, A. Imamovic, K. Kampel-kettner et al., External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology, European Urology, vol.57, issue.1, pp.102-111, 2010.
DOI : 10.1016/j.eururo.2008.11.033

R. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam et al., Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2570, 1999.
DOI : 10.1200/JCO.1999.17.8.2530

D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan et al., Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor???Targeted Agents: Results From a Large, Multicenter Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5794-5803, 2009.
DOI : 10.1200/JCO.2008.21.4809

B. Escudier, M. Goupil, C. Massard, and K. Fizazi, Sequential therapy in renal cell carcinoma. Cancer, pp.2321-2327, 2009.

W. Linehan, R. Srinivasan, and L. Schmidt, The genetic basis of kidney cancer: a metabolic disease, Nature Reviews Urology, vol.170, issue.5, pp.277-85, 2010.
DOI : 10.1038/nrurol.2010.47

J. Edeline, C. Vigneau, J. Patard, and N. Rioux-leclercq, Signalling pathways in renal-cell carcinoma: from the molecular biology to the future therapy], Bull Cancer, vol.97, pp.5-15, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00480057

A. Girgis, V. Iakovlev, B. Beheshti, J. Bayani, J. Squire et al., Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res, pp.5273-84, 2012.

R. Beroukhim, J. Brunet, D. Napoli, A. Mertz, K. Seeley et al., Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney, Cancer Research, vol.69, issue.11, pp.4674-81, 2009.
DOI : 10.1158/0008-5472.CAN-09-0146

T. Yoshimoto, K. Matsuura, S. Karnan, H. Tagawa, C. Nakada et al., High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma, The Journal of Pathology, vol.67, issue.4, pp.392-401, 2007.
DOI : 10.1002/path.2239

M. Brunelli, A. Eccher, S. Gobbo, V. Ficarra, G. Novara et al., Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma, Modern Pathology, vol.61, issue.1, pp.1-6, 2008.
DOI : 10.1038/modpathol.3800967

J. Sanjmyatav, K. Junker, S. Matthes, M. Muehr, D. Sava et al., Identification of Genomic Alterations Associated With Metastasis and Cancer Specific Survival in Clear Cell Renal Cell Carcinoma, The Journal of Urology, vol.186, issue.5, pp.2078-83, 2011.
DOI : 10.1016/j.juro.2011.06.050

N. Kroeger, T. Klatte, K. Chamie, P. Rao, F. Birkhäuser et al., Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer, pp.1547-54, 2013.

B. Wondergem, Z. Zhang, D. Huang, C. Ong, J. Koeman et al., Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma, Cancer Research, vol.72, issue.17, pp.4361-71, 2012.
DOI : 10.1158/0008-5472.CAN-11-2330

D. Matsuda, S. Khoo, A. Massie, M. Iwamura, J. Chen et al., Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett, pp.260-267, 2008.

F. Monzon, K. Alvarez, L. Peterson, L. Truong, R. Amato et al., Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis, Modern Pathology, vol.25, issue.11, 2011.
DOI : 10.1146/annurev.pathol.1.110304.100043

G. Dor?evi?, M. Ilija?, K. Had?isejdi?, I. Mari?i?, A. Grahovac et al., EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A, J Biomed Sci. Am J Pathol Feb, vol.19158, issue.2, pp.40-66593, 2001.

J. Garcia-donas, E. Esteban, L. Leandro-garcía, D. Castellano, A. Del-alba et al., Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study, The Lancet Oncology, vol.12, issue.12, pp.1143-50, 2011.
DOI : 10.1016/S1470-2045(11)70266-2

M. Morris, C. Ricketts, D. Gentle, F. Mcronald, N. Carli et al., Genomewide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene, pp.1390-401, 2011.

F. Gottardo, C. Liu, M. Ferracin, G. Calin, M. Fassan et al., Micro-RNA profiling in kidney and bladder cancers A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer, Urol Oncol. Gastroenterology. Feb, vol.25132, issue.52, pp.387-92, 2007.

D. Fiore, F. Charbonnier, F. Martin, C. Frerot, S. Olschwang et al., Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis, J Med Genet Cancer Chemother Pharmacol, vol.41, issue.1, pp.18-20, 2004.

B. Houk, C. Bello, D. Kang, and M. Amantea, A Population Pharmacokinetic Metaanalysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients, Clin Cancer Res, vol.6615, issue.27, pp.357-71, 2009.

R. Macfarlane, D. Heng, W. Xie, J. Knox, D. Mcdermott et al., The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer, pp.365-70, 2012.

D. Miled, O. Dionne, C. Terret, C. Segura-ferlay, C. Flechon et al., Sorafenib and sunitinib for elderly patients with renal cell carcinoma A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Geriatr Oncol. 2013 Ann Intern Med Mar Am J Kidney Dis Off J Natl Kidney Found Feb Charlson ME J Chronic Dis, vol.41303940, issue.805, pp.255-61, 1987.

Y. Neuzillet, Evaluation of co-morbidities and co-morbidity evaluation scores

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst Feb, vol.292, issue.3, pp.205-221, 2000.

S. Gupta, V. Parsa, L. Heilbrun, D. Smith, B. Dickow et al., Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs, Pfizer Laboratories. Sutent® Sunitinib Maleate Capsules [Internet], pp.794-800, 2006.

B. Pharma, Nexavar® Sorafenib film-coated tablets [Internet], 2006.

P. Karakiewicz, M. Sun, J. Bellmunt, V. Sneller, and B. Escudier, Prediction of Progression-Free Survival Rates After Bevacizumab Plus Interferon Versus Interferon Alone in Patients with Metastatic Renal Cell Carcinoma: Comparison of a Nomogram to the Motzer Criteria, European Urology, vol.60, issue.1, pp.48-56, 2011.
DOI : 10.1016/j.eururo.2010.12.011

M. Vickers, H. Harbi, T. Choueiri, C. Kollmannsberger, S. North et al., Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients, Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma, 1990.

R. Iacovelli, G. Cartenì, C. Sternberg, M. Milella, M. Santoni et al., Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort, European Journal of Cancer, vol.49, issue.9, 1990.
DOI : 10.1016/j.ejca.2013.02.032

E. Arai, S. Ushijima, H. Tsuda, H. Fujimoto, F. Hosoda et al., Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome, Clinical Cancer Research, vol.14, issue.17, pp.5531-5540, 2008.
DOI : 10.1158/1078-0432.CCR-08-0443

M. Kim, T. Oskarsson, S. Acharyya, D. Nguyen, X. Zhang et al., Tumor Self-Seeding by Circulating Cancer Cells, Cell, vol.139, issue.7, pp.1315-1341, 2009.
DOI : 10.1016/j.cell.2009.11.025

URL : http://doi.org/10.1016/j.cell.2009.11.025